Cargando…

MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma

Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer. Myeloid Cell Leukemia 1 (MCL1), a pro-survival member of the Bcl-2 protein family is associated with chemo-resistance in CRC. The ability of MCL1 to inhibit apoptosis by binding to the BH3 domains of pro-apoptotic Bcl-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Dechen, Pfannenstiel, Luke, Demelash, Abeba, Phoon, Yee Peng, Mayell, Cameron, Cabrera, Claudia, Liu, Caini, Zhao, Junjie, Dermawan, Josephine, Patil, Deepa, DeVecchio, Jennifer, Kalady, Matthew, Souers, Andrew J., Phillips, Darren C., Li, Xiaoxia, Gastman, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766550/
https://www.ncbi.nlm.nih.gov/pubmed/35042842
http://dx.doi.org/10.1038/s41419-021-04334-y
_version_ 1784634554568409088
author Fu, Dechen
Pfannenstiel, Luke
Demelash, Abeba
Phoon, Yee Peng
Mayell, Cameron
Cabrera, Claudia
Liu, Caini
Zhao, Junjie
Dermawan, Josephine
Patil, Deepa
DeVecchio, Jennifer
Kalady, Matthew
Souers, Andrew J.
Phillips, Darren C.
Li, Xiaoxia
Gastman, Brian
author_facet Fu, Dechen
Pfannenstiel, Luke
Demelash, Abeba
Phoon, Yee Peng
Mayell, Cameron
Cabrera, Claudia
Liu, Caini
Zhao, Junjie
Dermawan, Josephine
Patil, Deepa
DeVecchio, Jennifer
Kalady, Matthew
Souers, Andrew J.
Phillips, Darren C.
Li, Xiaoxia
Gastman, Brian
author_sort Fu, Dechen
collection PubMed
description Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer. Myeloid Cell Leukemia 1 (MCL1), a pro-survival member of the Bcl-2 protein family is associated with chemo-resistance in CRC. The ability of MCL1 to inhibit apoptosis by binding to the BH3 domains of pro-apoptotic Bcl-2 family members is a well-studied means by which this protein confers resistance to multiple anti-cancer therapies. We found that specific DNA damaging chemotherapies promote nuclear MCL1 translocation in CRC models. In p53(null) CRC, this process is associated with resistance to chemotherapeutic agents, the mechanism of which is distinct from the classical mitochondrial protection. We previously reported that MCL1 has a noncanonical chemoresistance capability, which requires a novel loop domain that is distinct from the BH3-binding domain associated with anti-apoptotic function. Herein we disclose that upon treatment with specific DNA-damaging chemotherapy, this loop domain binds directly to alpha-enolase which in turn binds to calmodulin; we further show these protein−protein interactions are critical in MCL1’s nuclear import and chemoresistance. We additionally observed that in chemotherapy-treated p53(−/−) CRC models, MCL1 nuclear translocation confers sensitivity to Bcl-xL inhibitors, which has significant translational relevance given the co-expression of these proteins in CRC patient samples. Together these findings indicate that chemotherapy-induced MCL1 translocation represents a novel resistance mechanism in CRC, while also exposing an inherent and targetable Bcl-xL co-dependency in these cancers. The combination of chemotherapy and Bcl-xL inhibitors may thus represent a rational means of treating p53(−/−) CRC via exploitation of this unique MCL1-based chemoresistance mechanism.
format Online
Article
Text
id pubmed-8766550
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87665502022-02-04 MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma Fu, Dechen Pfannenstiel, Luke Demelash, Abeba Phoon, Yee Peng Mayell, Cameron Cabrera, Claudia Liu, Caini Zhao, Junjie Dermawan, Josephine Patil, Deepa DeVecchio, Jennifer Kalady, Matthew Souers, Andrew J. Phillips, Darren C. Li, Xiaoxia Gastman, Brian Cell Death Dis Article Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer. Myeloid Cell Leukemia 1 (MCL1), a pro-survival member of the Bcl-2 protein family is associated with chemo-resistance in CRC. The ability of MCL1 to inhibit apoptosis by binding to the BH3 domains of pro-apoptotic Bcl-2 family members is a well-studied means by which this protein confers resistance to multiple anti-cancer therapies. We found that specific DNA damaging chemotherapies promote nuclear MCL1 translocation in CRC models. In p53(null) CRC, this process is associated with resistance to chemotherapeutic agents, the mechanism of which is distinct from the classical mitochondrial protection. We previously reported that MCL1 has a noncanonical chemoresistance capability, which requires a novel loop domain that is distinct from the BH3-binding domain associated with anti-apoptotic function. Herein we disclose that upon treatment with specific DNA-damaging chemotherapy, this loop domain binds directly to alpha-enolase which in turn binds to calmodulin; we further show these protein−protein interactions are critical in MCL1’s nuclear import and chemoresistance. We additionally observed that in chemotherapy-treated p53(−/−) CRC models, MCL1 nuclear translocation confers sensitivity to Bcl-xL inhibitors, which has significant translational relevance given the co-expression of these proteins in CRC patient samples. Together these findings indicate that chemotherapy-induced MCL1 translocation represents a novel resistance mechanism in CRC, while also exposing an inherent and targetable Bcl-xL co-dependency in these cancers. The combination of chemotherapy and Bcl-xL inhibitors may thus represent a rational means of treating p53(−/−) CRC via exploitation of this unique MCL1-based chemoresistance mechanism. Nature Publishing Group UK 2022-01-18 /pmc/articles/PMC8766550/ /pubmed/35042842 http://dx.doi.org/10.1038/s41419-021-04334-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Fu, Dechen
Pfannenstiel, Luke
Demelash, Abeba
Phoon, Yee Peng
Mayell, Cameron
Cabrera, Claudia
Liu, Caini
Zhao, Junjie
Dermawan, Josephine
Patil, Deepa
DeVecchio, Jennifer
Kalady, Matthew
Souers, Andrew J.
Phillips, Darren C.
Li, Xiaoxia
Gastman, Brian
MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
title MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
title_full MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
title_fullStr MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
title_full_unstemmed MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
title_short MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
title_sort mcl1 nuclear translocation induces chemoresistance in colorectal carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766550/
https://www.ncbi.nlm.nih.gov/pubmed/35042842
http://dx.doi.org/10.1038/s41419-021-04334-y
work_keys_str_mv AT fudechen mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT pfannenstielluke mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT demelashabeba mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT phoonyeepeng mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT mayellcameron mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT cabreraclaudia mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT liucaini mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT zhaojunjie mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT dermawanjosephine mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT patildeepa mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT devecchiojennifer mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT kaladymatthew mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT souersandrewj mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT phillipsdarrenc mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT lixiaoxia mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma
AT gastmanbrian mcl1nucleartranslocationinduceschemoresistanceincolorectalcarcinoma